Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer.

Nicole M Engel-Nitz Mary G Johnson Michael P Johnson Ashley S Cha-Silva Samantha K Kurosky Xianchen Liu

Published in: Patient preference and adherence (2023)

In this real-world study, >85% of patients started palbociclib at 125 mg/day and 1 in 3 had dose reductions during the follow-up. Patients were generally adherent and persistent with palbociclib. Older age, bone-only disease, and low-income levels were associated with early discontinuation or non-adherence. Further studies are needed to understand the associations of clinical and economic outcomes with palbociclib adherence and persistence.

Keyphrases

metastatic breast cancer
epidermal growth factor receptor
end stage renal disease
tyrosine kinase
chronic kidney disease
advanced non small cell lung cancer
endothelial cells
glycemic control
physical activity
peritoneal dialysis
patient reported outcomes
adipose tissue
insulin resistance
body composition